Browse FCGR3A

Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Secreted. Note=Exists also as a soluble receptor.
Domain PF13895 Immunoglobulin domain
Function

Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006909 phagocytosis
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
Molecular Function GO:0019864 IgG binding
GO:0019865 immunoglobulin binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04380 Osteoclast differentiation
hsa04650 Natural killer cell mediated cytotoxicity
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485: Role of phospholipids in phagocytosis
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCGR3A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FCGR3A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27777574Colorectal carcinomaPromote immunityCRC-NK cells displayed underexpression of CD16, NKG2D, DNAM-1, CD161, NKp46, and NKp30 activating receptors, while inhibitory receptors CD85j and NKG2A were overexpressed. This inhibited phenotype affected cytotoxic functionality against CRC cells and interferon-γ production.
18307255B cell non-Hodgkin lymphoma; Chronic Lymphocytic Leukemia; Breast CarcinomaPromote immunity (T and NK cell function); increase the efficacy of immunotherapyOur results show that CD16(+)V gamma 9 V delta 2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or V gamma 9 V delta 2 T cells alone.
27496866Head and Neck CarcinomaPromote immunity (NK cell function); essential for immunotherapyCetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is important for inducing antitumor cellular immunity. Cetuximab-activated NK cells upregulate the costimulatory receptor CD137 (4-1BB), which, when triggered by agonistic mAb urelumab, might enhance NK-cell functions, to promote T-cell-based immunity.
23690482Acute Myeloid LeukemiaPromote immunity (NK cell function); essential for immunotherapyWe determined whether a novel bispecific killer cell engager (BiKE) signaling through CD16 and targeting CD33 could activate NK cells at high potency against acute myelogenous leukemia (AML) targets. Combination treatment with CD16 × 33 BiKE and ADAM17 inhibitor resulted in inhibition of CD16 shedding in NK cells, and enhanced NK cell activation.
27742794Renal Cell CarcinomaPromote immunityFCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Fc-gamma receptors (FCGRs) are expressed on immune cells, bind to antibodies, and trigger antibody-induced cell-mediated antitumor responses when tumor-reactive antibodies are present. The affinity of the FCGR/antibody interaction is variable and dependent upon FCGR polymorphisms. When higher-affinity genotypes for FCGR2A, FCGR3A, and FCGR2C were considered together, they were associated with significantly increased tumor shrinkage and prolonged survival in response to HD-IL2.
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCGR3A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCGR3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4680.4
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6370.809
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3440.86
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.710.274
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1660.897
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.8350.335
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.997
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2140.916
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.230.918
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.240.602
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2710.742
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4140.0733
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCGR3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.218.83.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 594011.128.90.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47028.6-28.60.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGR3A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGR3A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGR3A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGR3A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCGR3A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCGR3A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCGR3A
NameFc fragment of IgG, low affinity IIIa, receptor (CD16a)
Aliases CD16a; Fc fragment of IgG, low affinity IIIa, receptor for (CD16); FCGRIII; FCRIIIA; IGFR3; IMD20; CD16a ant ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCGR3A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FCGR3A.
ID Name Drug Type Targets #Targets
DB00002CetuximabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00005EtanerceptBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00028Immune Globulin HumanBiotechC3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......11
DB00051AdalimumabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00054AbciximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00056Gemtuzumab ozogamicinBiotechC1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00072TrastuzumabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......13
DB00073RituximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00074BasiliximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......13
DB00075MuromonabBiotechC1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......15
DB00078Ibritumomab tiuxetanBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00081TositumomabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00087AlemtuzumabBiotechC1QA, C1QB, C1QC, C1R, CD52, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3 ......11
DB00092AlefaceptBiotechC1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......11
DB00095EfalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00108NatalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00110PalivizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......10
DB00111DaclizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00112BevacizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB06607CatumaxomabBiotechCD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B6
DB11767SarilumabBiotechFCGR1A, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IL6R6
DB12023BenralizumabBiotechFCGR3A, IL5RA2